581
Participants
Start Date
November 3, 2022
Primary Completion Date
February 18, 2023
Study Completion Date
February 13, 2024
Panblok + MF59 Dose 1
Pharmaceutical form: suspension for injection Route of administration: intramuscular
Panblok + MF59 Dose 2
Pharmaceutical form: suspension for injection Route of administration: intramuscular
Unadjuvanted Panblok Dose 3
Pharmaceutical form: liquid for injection Route of administration: intramuscular
Preferred Primary Care Physicians Site Number : 8400015, Pittsburgh
Preferred Primary Care Physicians, Inc. Site Number : 8400002, Pittsburgh
M3 Wake Research Inc Site Number : 8400010, Raleigh
Velocity Clinical Research Anderson Site Number : 8400016, Anderson
CenExel ACMR (Atlanta Center for Medical Research) Site Number : 8400022, Atlanta
St Johns Center for Clinical Research Site Number : 8400021, Saint Augustine
Velocity Clinical Research-Hallandale Beach Site Number : 8400026, Hallandale
Research Centers of America Site Number : 8400024, Hollywood
Suncoast Research Associates, LLC Site Number : 8400008, Miami
WR-ClinSearch, LLC Site Number : 8400003, Chattanooga
Velocity Clinical Research Valparaiso Site Number : 8400007, Valparaiso
Velocity Clinical Research Site Number : 8400027, Metairie
Velocity Clinical Research Site Number : 8400019, Austin
JBR Clinical Research Site Number : 8400005, Salt Lake City
Foothill Family Research-South Site Number : 8400009, Salt Lake City
Centricity Research-Mesa Site Number : 8400006, Mesa
Sanofi Pasteur, a Sanofi Company
INDUSTRY